| |
| associate professor fei mao |
|
|
| 发布时间：2019-11-29 访问次数:571 作者: |
 contact information
office:room 431, researching building 18 email: office phone: 86 21 6425 2584 office fax: 86 21 6425 2584
education 2014.06ph.d. medicinal chemistry, sun yat-sen university, guangzhou, r.p. china 2009.06b.s. applied chemistry, shenyang pharmaceutical university, shenyang, p. r. china
professional experience 2018-nowassociate professor, east china university of science and technology, shanghai, p. r. china 2016-2018 assistant professor, east china university of science and technology, shanghai, p. r. china 2014-2016 postdoctor, east china university of science and technology, shanghai, p. r. china
research interests discovery of potential agents for the treatment of endometrial cancer discovery of multi-target anti-alzheimer’s disease candidates repurposing and redevelopment of old drugs
publication wenwen liu#, huan wang#, xiaokang li#, yixiang xu, jian zhang, wei wang, qi gong, xiaoxia qiu, jin zhu, fei mao*, haiyan zhang*, jian li*. design, synthesis and evaluation of vilazodone-tacrine hybrids as multitarget-directed ligands against depression with cognitive impairment. bioorg. med. chem. 2018, 26, 3117–3125. wei ni#, huan wang#, xiaokang li#, xinyu zheng#, manjiong wang, jian zhang, qi gong, dazheng ling, fei mao*, haiyan zhang*, jian li*. novel tadalafil derivatives ameliorates scopolamine-induced cognitive impairment in mice via inhibition of acetylcholinesterase (ache) and phosphodiesterase 5 (pde5). acs chem. neurosci. 2018, 9, 1625–1636. baoli li#, shuaishuai ni#, fei mao#, feifei chen, yifu liu, hanwen wei, wenhua chen, jin zhu, lefu lan*, jian li*. novel terminal bipheny-based diapophytoene desaturases (crtn) inhibitors as anti-mrsa/visr/lrsa agents with reduced herg activity. j. med. chem. 2018, 61, 224–250. fei mao#, huan wang#, wei ni#, xinyu zheng, manjiong wang, keting bao, dazheng ling, xiaokang li, yixiang xu, haiyan zhang*, jian li*. design, synthesis, and biological evaluation of orally available first-generation dual-target selective inhibitors of acetylcholinesterase (ache) and phosphodiesterase 5 (pde5) for the treatment of alzheimer’s disease. acs chem. neurosci. 2018, 9, 328–345. hanwen wei#, fei mao#, shuaishuai ni#, feifei chen, baoli li, xiaoxia qiu, linghao hu, manjiong wang, xinyu zheng, jin zhu, lefu lan*, jian li*. discovery of novel piperonyl derivatives as diapophytoene desaturase inhibitors for the treatment of methicillin-, vancomycin- and linezolid-resistant staphylococcus aureus infections. eur. j. med. chem. 2018, 145, 235–251. yi-xiang xu#, huan wang#, xiao-kang li, sheng-nan dong, wen-wen liu, qi gong, tian-duan-yi wang, yun tang, jin zhu, jian li*, hai-yan zhang*, fei mao*. discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of alzheimer's disease. eur. j. med. chem. 2018, 143, 33–47. xiaokang li#, huan wang#, yixiang xu, wenwen liu, xiaoxia qiu, jin zhu, fei mao*, haiyan zhang*, jian li*. novel vilazodone-tacrine hybrids as potential multitarget-directed ligands for the treatment of alzheimer’s disease accompanied with depression: design, synthesis and biological evaluation. acs chem. neurosci. 2017, 8, 2708–2721. yanli lu#, fei mao#, xiaokang li, xinyu zheng, manjiong wang, qing xu, jin zhu, and jian li*. discovery of potent, selective stem cell factor receptor/platelet derived growth factor receptor alpha (c-kit/pdgfrα) dual inhibitor for the treatment of imatinib-resistant gastrointestinal stromal tumors (gists). j. med. chem. 2017, 60, 5099–5119. xiaokang li#, huan wang#, zhengyu lu, xinyu zheng, wei ni, jin zhu, yan fu, fulin lian, naixia zhang, jian li*, haiyan zhang*, and fei mao*. development of multifunctional pyrimidinylthiourea derivatives as potential anti-alzheimer agents. j. med. chem. 2016, 59, 8326−8344. fei mao#, qingya kong#, wei ni, xiang xu, dazheng ling, zhengyu lu, jian li*. melting point distribution analysis of the global approved and discontinued drugs: a research for improving the success chance of drug design and discovery. chemistryopen, 2016, 5, 357–368. fei mao, wei ni, xiang xu, hui wang, jing wang, min ji, jian li*. chemical structure-related drug-like criteria of global approved drugs. molecules 2016, 21, 75; doi:10.3390/molecules21010075. dengwei wu#, fei mao#, yan ye, jian li, chuanlian xu*, xiaomin luo, jing chen*, xu shen. policresulen as a novel inhibitor of ns2b/ns3 protease efficiently suppressed the replication of denv2 virus. acta pharmacol. sin. 2015, 36, 1126-1136. fei mao, jianheng li, hui wei, ling huang*, xingshu li*. tacrine-propargylamine derivatives with improved acetylcholinesterase inhibitory activity and lower hepatotoxicity as a potential lead compound for the treatment of alzheimer’s disease.j. enzym. inhib. med. chem.2015,30, 995-1001. fei mao, jun yan, jian-heng li, yang sun, xian jia, ling huang*, xing-shu li*. new multi-target-directed small molecules against alzheimer's disease: a combination of resveratrol and clioquinol. org. biomol. chem. 2014, 12, 5936-5944. fei mao, jian-wen chen*, qi zhou, zong-hua luo, li huang, xing-shu li*. novel tacrine–ebselen hybrids with improved cholinesterase inhibitory, hydrogen peroxide and peroxynitrite scavenging activity. bioorg. med. chem. lett.2013, 23, 6737-6742. fei mao, ling huang, zong-hua luo, anqiu liu, chuan-jun lu, zhi-yong xie*, xingshu li*. o-hydroxyl or o-amino benzylamine-tacrine hybrids: multifunctional biometals chelators, antioxidants, and inhibitors of cholinesterase activity and amyloid-beta aggregation. bioorgan. med. chem.2012, 20, 5884-5892.
|
|
|
|
